What Genexpath does

Genexpath is a molecular diagnostics company specializing in the precise genetic characterization of complex cancers, particularly non-Hodgkin's lymphomas and sarcomas. The company develops and commercializes CE-IVD diagnostic kits and research-use products built on its proprietary RT-MLPSeq technology (Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification with High-Throughput Sequencing), which enables semi-quantitative analysis of multiple genetic markers, mutations, and chromosomal translocations in a single assay using exon-exon junction targeting and Unique Molecular Identifiers. Core products include the LymphoSign Kit (CE-IVD, classifying 80+ NHL subtypes via 130+ genetic markers), the SarcomaFusion Test (CE-IVD, analyzing 140+ fusion transcripts), and the LymphoTranscript Test for peripheral T-cell lymphomas. These are complemented by the RT-MIS bioinformatics platform, an AI-driven classification tool trained on 3,000+ tumor profiles referencing WHO 2017 standards.

Genexpath operates as a subsidiary of the CLINISCIENCES GROUP, which provides worldwide distribution infrastructure spanning 20+ European countries, South Korea, the USA, and Brazil. The company sells CE-IVD diagnostic kits in multiple reaction-size configurations, offers custom panel solutions (10-100 markers) for research and clinical studies, and supplies research products through the CLINISCIENCES catalog. Pricing is quote-based through local distributors, with kit sales representing a one-time-license revenue model and custom panel services offered as project-based engagements. Customers include hospital and clinical pathology laboratories (primary), pharmaceutical and biotech companies, and public research centers.

The company holds ISO 13485:2016 certification through its parent group and integrates its workflow with Illumina sequencing platforms (MiSeq, NextSeq 500/550). Founded in 2020 in Rouen, France, Genexpath has received two rounds of incubation support from Normandie Incubation. Its RT-MLPSeq-based workflow requires minimal RNA input (50-500 ng), is compatible with FFPE samples, and delivers results within approximately 24 hours, positioning the company in the niche but clinically meaningful segment of high-specificity cancer subtyping diagnostics.

Name

Genexpath

Website

https://genexpath.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Genexpath is a French molecular diagnostics subsidiary of CLINISCIENCES GROUP that develops CE-IVD kits and research panels built on proprietary RT-MLPSeq technology for the genetic characterization of non-Hodgkin's lymphomas, sarcomas, and T-cell lymphomas, selling to clinical laboratories, pharmaceutical companies, and research centers via a global distributor network.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers) (HLAAAMAI)

Keywords

• Molecular diagnostics
• Cancer characterization
• RT-MLPSeq technology
• In vitro diagnostics
• Lymphoma classification

Headquarters

HQ city

Rouen

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel

Revenue model

1. Diagnostic Kits: Sale of CE-IVD diagnostic kits including LymphoSign Kit (8, 16, 24, 48 reaction configurations) for non-Hodgkin's lymphoma classification, LymphoTranscript for peripheral T-cell lymphomas, and SarcomaFusion for sarcoma characterization.
2. Custom Panel Solutions: Custom panel development and production services for research projects, preclinical and clinical studies. Available for 32 or 64 samples, enabling gene expression and fusion transcript analysis for 10-100 markers of interest.
3. Research Products: Sale of research products including human biological samples (cardiac, skin, bone marrow tissues), antibodies, molecular biology kits, cell culture systems, nanomaterials, and lab reagents through the CLINISCIENCES catalog.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Genexpath develops and commercializes CE-IVD molecular diagnostic kits and custom panels based on its proprietary RT-MLPSeq technology for the characterization of cancers including non-Hodgkin's lymphomas, sarcomas, and peripheral T-cell lymphomas. Its flagship LymphoSign Kit simultaneously analyzes over 130 genetic markers to classify more than 80 NHL subtypes within 24 hours from tumor RNA, complemented by the RT-MIS AI-driven bioinformatics platform trained on 3,000+ tumor profiles.

Product overview

Genexpath is a molecular diagnostics company offering a portfolio of CE-IVD diagnostic tests and research-use products built on their proprietary RT-MLPSeq technology platform. The core offering includes the LymphoSign Kit (CE-IVD) for non-Hodgkin's lymphoma classification analyzing 130+ genetic markers, the SarcomaFusion Test (CE-IVD) for sarcoma diagnosis with 140+ fusion transcripts, and the LymphoTranscript Test for peripheral T-cell lymphoma characterization. These diagnostic products are complemented by the RT-MIS bioinformatics platform for data analysis and custom panel services for research applications. The company operates under the CLINISCIENCES GROUP and provides products to hospitals, research centers, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• LymphoSign: CE-IVD diagnostic kit for classification of non-Hodgkin's lymphoma subtypes using RT-MLPSeq technology analyzing over 130 genetic markers
• SarcomaFusion
• LymphoTranscript
• RT-MIS
• RT-MLPSeq

Products and services

• LymphoSign Kit CE-IVD diagnostic kit for classification of over 80 Non-Hodgkin's lymphoma subtypes through RT-MLPSeq analysis of 130+ genetic markers, with AI-driven classification via RT-MIS software. Available in 8, 16, 24, and 48 reaction configurations.
• SarcomaFusion Test CE-IVD diagnostic test for characterization of sarcomas by analyzing over 140 fusion transcripts using RT-MLPSeq technology.
• LymphoTranscript Test Diagnostic test for characterization of peripheral T-cell lymphomas through fusion transcript analysis using RT-MLPSeq technology.
• RT-MIS Platform Bioinformatics platform for rapid analysis of NGS sequencing data, providing gene expression signatures and AI-predicted classifications for cancer diagnostics based on a database of more than 3,000 tumor profiles.
• Custom RT-MLPSeq Panels Custom RT-MLPSeq panel solution allowing selection of 10-100 markers of interest for research projects, preclinical and clinical studies, available for 32 or 64 samples, with turnkey in vitro testing and bioinformatics analysis.

Quantifiable outcome

• Classification of 80+ Non-Hodgkin's lymphoma subtypes
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• IlluminacoreTechnology or IntegrationIllumina sequencing platforms (MiSeq, NextSeq 500, NextSeq 550) are used for RT-MLPSeq library sequencing. The LymphoSign kit workflow is designed for compatibility with Illumina sequencers, enabling integration of Genexpath diagnostic solutions into existing laboratory infrastructure.
• CliniSciences GroupcoreChannel Partner/ Reseller/ DistributorCliniSciences Group is the parent company and primary distributor for Genexpath products. They maintain worldwide distribution capabilities covering Europe, Americas, and Asia with customer service and technical support infrastructure.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Regional players

• NeoGenomics: NeoGenomics is a US-based clinical reference lab running lymphoma NGS panels (e.g., Lymphoma Profile) at scale, competing for the same clinical pathology customers Genexpath sells kits into, especially in North America.

Emerging players

• Personalis: Personalis offers the ImmunoID Next platform for tumor immunogenomics and is expanding into hematologic cancer applications, positioning it as a competing NGS-based oncology diagnostics vendor with deeper US presence.

Direct peers

• HTG Molecular Diagnostics: HTG offers targeted gene-expression and fusion-detection assays for oncology using a proprietary extraction-free chemistry run on NGS, closely mirroring Genexpath's RT-MLPSeq FFPE workflow and lymphoma/sarcoma indication focus.
• ArcherDX (Invitae): ArcherDX's Anchored Multiplex PCR (AMP) chemistry delivers targeted NGS fusion and expression profiling for solid tumors and hematologic malignancies, a direct technical analogue to Genexpath's RT-MLPSeq.
• SOPHiA GENETICS: SOPHiA provides AI-driven analysis of NGS oncology panels including lymphoma applications, with a community-based data-sharing model analogous to Genexpath's RT-MIS tumor-profile database.
• Asuragen (now part of Bio-Techne): Asuragen developed the QuantideX qPCR fusion assays and Signatera-style oncology kits targeting hematologic malignancies and sarcomas, a similar niche-IVD oncology diagnostic franchise to Genexpath.

Broad incumbents

• Illumina (AmpliSeq for Illumina): Illumina supplies the sequencers Genexpath's workflow depends on, plus its own AmpliSeq targeted oncology panels — making Illumina both a critical partner and a potential competitive incumbent.
• Qiagen (QIAseq targeted panels): Qiagen sells a broad portfolio of oncology NGS panels and bioinformatics (QIAseq, IPA) and competes with Genexpath across research and clinical diagnostics with much greater scale.
• Thermo Fisher Scientific (Oncomine panels): Thermo Fisher's Oncomine NGS panels and Ion Torrent platform offer targeted lymphoma and solid tumor profiling, providing a competing turnkey workflow for clinical pathology labs evaluating Genexpath's offering.
• NanoString Technologies (now Bruker Spatial Biology): NanoString's nCounter and GeoMx platforms deliver multiplex gene-expression profiling in oncology, a comparable multi-marker approach to Genexpath's RT-MLPSeq with broader market adoption.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/clinisciences

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genexpath